Merck has submitted data on its COVID-19 pill to the FDA after a successful trial; air, land, and ferry travelers will be allowed into the United States in November if they show proof of vaccination; 13 of 33 certified community behavioral health clinics in Michigan will be reimbursed by Medicaid.
Molnupiravir is a twice-daily pill developed by Merck that has been shown to reduce the risk of hospitalization and death caused by COVID-19, and it could be widely used as a treatment in the near future if approved for emergency use, The Washington Post reported. Molnupiravir is an antiviral pill given to people with mild to moderate cases of COVID-19 to prevent them from developing severe cases. Merck has submitted data to the FDA after a successful trial and plans to apply for emergency authorization in other countries as well. An FDA advisory committee will meet on November 30 to discuss the emergency use authorization request and set a timeline for molnupiravir’s use.
The White House has decided that foreign travelers vaccinated against COVID-19 will be allowed into the United States starting November 8, NPR reported. Those traveling by air will have to show proof of vaccination and a negative COVID-19 test taken within 3 days before boarding the plane. Land and ferry travelers will also have to show proof of vaccination, but will not be required to get tested. The White House will clarify what counts as proof of vaccination in the coming weeks, emphasizing there will be very limited exceptions to the requirements.
Starting this month, 13 mental health and addiction clinics across Michigan will receive the same Medicaid funding as any other health center, the Associated Press reported. The selected certified community behavioral health clinics (CCBHCs) will now be fully reimbursed by Medicaid instead of relying on grants to supplement costs. There are 20 other CCBHCs providing 24-hour crisis care in Michigan that have not yet been approved for Medicaid reimbursement. This decision was made in an effort to bridge the divide between mental and physical health in terms of both funding and stigma, and it will allow for more staffing and resources for these clinics.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More